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Abstract 1 
Aicardi-Goutières syndrome (AGS) is a rare, genetically determined early-onset progressive 2 
encephalopathy. To date, mutations in six genes have been identified as etiologic for AGS. Our Japanese 3 
nationwide AGS survey identified six AGS individuals without a molecular diagnosis; we performed 4 
whole exome sequencing on three of these individuals. After removal of the common polymorphisms 5 
found in SNP databases, we were able to identify IFIH1 heterozygous missense mutations in all three. In 6 
vitro functional analysis revealed that IFIH1 mutations increased type I interferon production, and the 7 
transcription of interferon-stimulated genes were elevated. IFIH1 encodes MDA5, and mutant MDA5 8 
lacked ligand-specific responsiveness, similarly to the dominant IFIH1 mutation responsible for the SLE 9 
mouse model that results in type I interferon overproduction. This study suggests that the IFIH1 10 
mutations are responsible for the AGS phenotype due to an excessive production of type I interferon. 11 
 Aicardi-Goutières syndrome (AGS [MIM 225750]) is a rare, genetically determined early-onset 1 
progressive encephalopathy1. Individuals affected with AGS typically suffer from progressive 2 
microcephaly associated with severe neurological symptoms, such as hypotonia, dystonia, seizures, 3 
spastic quadriplegia, and severe developmental delay2. On brain imaging, AGS is characterized by basal 4 
ganglia calcification, white matter abnormalities, and cerebral atrophy3, 4. Cerebrospinal fluid (CSF) 5 
analyses show chronic lymphocytosis and elevated levels of IFN-α and neopterin3-5. AGS individuals are 6 
often misdiagnosed as having intrauterine infections, such as TORCH syndrome, because of the 7 
similarities of these disorders, particularly the intracranial calcifications1. In AGS, etiological mutations 8 
have been reported in the following six genes: TREX1 (MIM 606609), which encodes a DNA 9 
exonuclease; RNASEH2A (MIM 606034), RNASEH2B (MIM 610326), and RNASEH2C (MIM 610330), 10 
which together comprise the RNase H2 endonuclease complex; SAMHD1 (MIM 606754), which encodes 11 
a deoxynucleotide triphosphohydrolase; and ADAR1 (MIM 146920), which encodes an adenosine 12 
deaminase6-9. Although more than 90% of AGS individuals harbor etiological mutations in one of these 13 
six genes, some AGS-affected individuals presenting with the clinical characteristics of AGS still lack a 14 
genetic diagnosis, suggesting the existence of additional AGS associated genes1.  15 
 We recently conducted a nationwide survey of AGS in Japan and reported 14 AGS individuals10. 16 
We have since recruited three other Japanese AGS individuals, and among these 17 individuals, we have 17 
identified 11 individuals with etiologic mutations; namely, TREX1 mutations in six, SAMHD1 mutations 18 
in three, and RNASEH2A and RNASEH2B mutations in one each. Of the remaining six individuals 19 
without a molecular diagnosis, trio-based whole exome sequencing was performed in three whose parents 20 
also agreed to participate in further genome-wide analyses (Figure 1A). Genomic DNA from each 21 
individual and their parents was enriched for protein-coding sequences, followed by massively parallel 22 
 5 
sequencing. The extracted non-synonymous or splice-site variants were filtered to remove those with 1 
minor allele frequencies (MAF) >0.01 in dbSNP137. To detect de novo variants, any variants observed in 2 
family members, listed in Human Genetic Variation Database (HGVD), or variants with MAF >0.02 in 3 
our in-house exome database were removed. To detect autosomal recessive (AR), compound 4 
heterozygous (CH), or X-linked (XL) variants, those with MAF >0.05 in our in-house database were 5 
removed (Figure S1). All samples were collected with the written informed consents by parents, and the 6 
study protocol was approved by the ethical committee of Kyoto University Hospital in accordance with 7 
the Declaration of Helsinki. 8 
After common polymorphisms were removed, we identified a total of 40, 18, 89, and 22 candidate 9 
variants under the de novo, AR, CH, and XL inheritance models, respectively, that were present in at least 10 
one of the three individuals (Table S1). Among them, missense mutations were identified in IFIH1 (MIM 11 
606951, RefSeq: NM_022168.2), which encodes MDA5 (NP_071451.2). These missense mutations are 12 
c.1354G>A, p.Ala452Thr, in AGS-1; c.1114C>T, p.Leu372Phe, in AGS-2; and c.2336G>A, 13 
p.Arg779His, in AGS-3 (Figure 1B). None of the mutations are found in HGVD, including the 1208 14 
Japanese samples, or our in-house exome database of 312 Japanese individuals. Multiple-sequence 15 
alignment using ClustalW2 revealed that each of the amino acids affected by these mutations are 16 
conserved among mammals (Figure1B). The subsequent amino acid alterations were all suggested to be 17 
disease-causing in at least one of the four function-prediction programs used (Table 1). None of the other 18 
genes identified in the de novo inheritance model, or any of the genes identified in the other three 19 
inheritance models, were mutated in all three individuals. The IFIH1 mutations identified were validated 20 
by Sanger sequencing. The other coding exons of IFIH1 were also examined by Sanger sequencing, and 21 
no other mutations were found. 22 
 6 
 MDA5 is one of the cytosolic pattern recognition receptors that recognizes double-stranded RNA 1 
(dsRNA)11. MDA5 consists of N-terminal tandem CARD domains, a central helicase domain, and a 2 
C-terminal domain (Figure 1C). When bound to dsRNA, MDA5 forms a closed, C-shaped ring structure 3 
around the dsRNA stem, and excludes the tandem CARD as well as creates filamentous oligomer on 4 
dsRNA12. It is hypothesized that the tandem CARD interacts each other, and activates MAVS on the 5 
mitochondrial outer membrane. Oligomerization of MAVS induces TBK1 activation, IRF3 6 
phosphorylation, and induction of type I interferon transcription, resulting in the activation of a large 7 
number of interferon-stimulated genes (ISGs).  8 
 The neurological findings of the individuals with these IFIH1 mutations are typical of AGS (Table 9 
S2). They were born with appropriate weights for their gestational ages without any signs of intrauterine 10 
infection. However, they all demonstrated severe developmental delay in early infancy associated with 11 
progressive microcephaly. No arthropathy, hearing loss, or ophthalmological problems were observed. As 12 
for extraneural features, all three individuals had at least one of the following autoimmune features: 13 
positivity for autoantibodies, hyperimmunoglobulinemia, hypocomplementemia, and thrombocytopenia. 14 
Notably, none of the individuals with IFIH1 mutations had chilblain lesions, although all the five 15 
individuals with TREX1 mutations and two of the three individuals with SAMHD1 mutations in the 16 
Japanese AGS cohort showed chilblain lesions10. Individuals with SAMHD1 mutations and IFIH1 17 
mutations both show autoimmune features; however, chilblain lesions have only been observed in 18 
individuals with SAMHD1 mutations10. 19 
 To predict the effects of the identified amino acid substitutions on MDA5, three-dimensional 20 
model structures of MDA5 mutants were generated from the crystal structure of human MDA5-dsRNA 21 
complex12 (Protein Data Bank (PDB) code; 4gl2), using PyMOL (Schroedinger) and MOE (Chemical 22 
 7 
Computing Group) (Figure S2A). The oligomeric model of MDA5 was generated using the electron 1 
microscopy imaging data of MDA5 filament lacking CARD domain22  (Electron Microscopic Data Bank 2 
(EMDB) code: 5444) (Figure S2B). The three amino acid substitutions in the AGS individuals are all 3 
located within the helicase domain (Figures 1C and S2A). Since Ala452 directly contacts the dsRNA 4 
ribose O2’ atom, the p.Ala452Thr substitution probably affect the binding affinity to dsRNA due to an 5 
atomic repulsion between the side chain of Thr452 and the dsRNA O2’ atom (Figures S2C and S2D). 6 
Leu372 is located adjacent to the ATP binding pocket, and the p.Leu372Phe substitution could increase 7 
the side chain volume of the binding pocket, affecting its ATP hydrolysis activity (Figures S2E and S2F). 8 
In our oligomeric model, Arg779 is located at the interface between the two monomers, which is 9 
consistent with the recent report showing that Lys777, close to Arg779, is in close proximity to the 10 
adjacent monomer12. Furthermore, in our model, Arg779 is in close to Asp572 on the surface of the 11 
adjacent monomer. We speculate that losing the positive charge due to the p.Arg779His substitution 12 
would possibly affect the electrostatic interaction between the MDA5 monomers (Figures S2G and S2H). 13 
To connect the identified IFIH1 mutations with the AGS phenotype, we examined the type I 14 
interferon signature in the individuals by performing reverse transcription quantitative PCR (RT-qPCR) 15 
of seven ISGs13. Peripheral blood mononuclear cells (PBMCs) from the three AGS individuals showed 16 
up-regulation of ISGs transcription (Figure 2), confirming the type I interferon signature in the 17 
individuals with IFIH1 mutations. 18 
 To elucidate the disease-causing capability of the identified IFIH1 mutations, three FLAG-tagged 19 
IFIH1 mutant plasmids containing these mutations were constructed using site-directed mutagenesis. 20 
These plasmids were transiently expressed on human hepatoma cell line Huh7 and the IFNB1 promoter 21 
activity as well as endogenous expression of IFIT1 ([MIM 147690]) was measured 48 hours after 22 
 8 
transfection14. The three mutant plasmids activated the IFNB1 promoter in Huh7 cells more strongly than 1 
the wild MDA5 and nearby missense variants reported in dbSNP (Figures 3 and S3). The up-regulation of 2 
endogenous IFIT1 was also observed in the transfected cells (Figure S4), suggesting that these AGS 3 
mutations enhance the intrinsic activation function of MDA5. Recent genome wide association studies 4 
(GWAS) showed association of the IFIH1 with various autoimmune diseases, such as systemic lupus 5 
erythematosus (SLE), type I diabetes, psoriasis, and vitiligo15 16 17 18. We examined IFNB1 promoter 6 
activity induced by the c.2836G>A (p.Ala946Thr) polymorphism (rs1990760) identified in the GWAS. 7 
Although the c.2836G>A polymorphism partially activated the promoter activity, the induced activity 8 
was lower than those of the AGS-derived mutants. In addition, the dominantly inherited SLE mouse 9 
model in the ENU-treated mouse colony is reported to have the IFIH1 mutation, c.2461G>A 10 
(p.Gly821Ser)14. These observations suggest that IFIH1 has strong association with various autoimmune 11 
diseases, especially SLE, which also has a type I interferon signature19. Since alteration of TREX1 has 12 
been reported to cause AGS as well as SLE20, it seems quite plausible for IFIH1 to also be involved in 13 
both AGS and SLE. Interestingly, all the individuals identified with IFIH1 mutations had autoantibodies, 14 
suggesting the contribution of IFIH1 mutations to autoimmune phenotypes.  15 
 To further delineate the functional consequences of the three IFH1 mutations, we measured the 16 
ligand-specific Ifnb mRNA induction by stimulating Ifih1null mouse embryonic fibroblasts (MEFs) 17 
reconstituted with retrovirus expressing the IFIH1 mutants by an MDA5-speicfic ligand, 18 
encephalomyocarditis virus (EMCV)21. None of the MEF cells expressing the three mutant IFIH1 19 
responded to the EMCV, which suggested that the MDA5 variants lacked the ligand-specific 20 
responsiveness. The response of the three AGS mutants against the MDA5-specific EMCV was similar to 21 
 9 
that of the p.Gly821Ser variant reported in the dominantly inherited SLE mouse model with type I 1 
interferon overproduction14 (Figures 4 and S5). 2 
During the revision of this manuscript, Rice et al. identified nine individuals with IFIH1 mutations, 3 
including the c.2336G>A mutation we identified, in a spectrum of neuroimmunological features 4 
consistently associated with enhanced type I interferon states including AGS 23. Although we agree that 5 
the IFIH1 mutations cause constitutive type I interferon activation, Rice et al. show the mutated MDA5 6 
proteins maintain ligand-induced responsiveness, which was not the case in our study. Since we measured 7 
the ligand-specific responsiveness of MDA5 in different experimental conditions, further analysis 8 
remains to be performed to reveal the biochemical mechanism of interferon overproduction by the 9 
mutated MDA5. 10 
 In conclusion, we identified mutations in IFIH1 as a cause of AGS. The individuals with the IFIH1 11 
mutations showed encephalopathy typical of AGS as well as the type I interferon signature with 12 
autoimmune phenotypes, but lacked the chilblains. Further analysis remains to elucidate the mechanism 13 
how the IFIH1 mutations identified in AGS cause the type I interferon overproduction.   14 
  15 
 10 
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Figure legends 1 
Figure 1 2 
Pedigree information for the AGS individuals and details of the IFIH1 mutations identified. 3 
(A) The pedigrees of the three families indicating the AGS probands. (B) Sanger sequencing 4 
chromatograms of the three IFIH1 mutations found in the AGS individuals. The locations of these 5 
mutations in the amino acid sequence of the MDA5 protein are shown in alignment with the conserved 6 
amino acid sequences from several species. This alignment was obtained using ClustalW2. The amino 7 
acids that are conserved with human are circled in red. (C) The MDA5 protein domain structure with the 8 
amino acid substitutions observed in these AGS individuals. 9 
 10 
Figure 2 11 
Quantitative RT-PCR (RT-qPCR) of a panel of seven ISGs in PBMCs obtained from the IFIH1-mutated 12 
individuals and healthy controls. RT-qPCR was performed as previously described14. The relative 13 
abundance of each transcript was normalized to the expression level of β-actin. Taqman probes used were 14 
the same as previous report13, except for ACTB (MIM 102630). Individual data were shown relative to a 15 
single calibrator (control 1). The experiment was performed in triplicate. Statistical significance was 16 
determined by Mann-Whitney U test, *p<0.05. 17 
 18 
Figure 3 19 
The effects of the three MDA5 variants on IFNB1 expression. Huh7 cells were transfected with a reporter 20 
gene containing IFNB1 promoter  (p-55C1B Luc), an empty vector (BOS) and expression vectors for 21 
 16 
FLAG-tagged human wild type IFIH1, c.2836G>A polymorphism (p.Ala946Thr) in the GWAS studies, 1 
and the identified IFIH1 mutants. Luciferase activity was measured 48 hours after transfection, and the 2 
MDA5 protein accumulation was examined by Western blotting as previously described14. FLAG 3 
indicates the accumulation of FLAG-tagged MDA5. Each experiment was performed in triplicate and 4 
data are mean ± S.E.M. Shown is a representative of two with consistent results. Statistical significance 5 
was determined by Student’s t-test. *p<0.05, **p<0.01. 6 
 7 
Figure 4 8 
Ifnb mRNA levels in Ifih1 deficient MEFs expressing IFIH1 mutants. The MEFs were infected with 9 
retroviruses encoding mouse wild type Ifih1, mouse Ifih1 with NM_027835.3:c.2461G>A (p.Gly821Ser) 10 
mutation, or the three AGS mutants of human IFIH1. 48hrs after the retroviral infection, these MEFs 11 
were infected with indicated multiplicity of infection (MOI) of EMCV for 6 hours, and Ifnb mRNA levels 12 
were measured by RT-qPCR. The relative abundance of each transcript was normalized to the expression 13 
level of 18S ribosomal RNA. Data are shown as mean ± S.E.M of triplicate samples. Shown is a 14 
representative of two independent experiments. Statistical significance was determined by Student’s t-test, 15 
*p<0.001. The expression of the retrovirally transduced FLAG-tagged constructs was confirmed by 16 




Functional predictions of the IFIH1 variants 
Individuals Nucleotide change Amino acid change SIFT PolyPhen2 Mutation Taster PROVEAN 
AGS-1 c.1354G>A p.Ala452Thr Tolerated Benign Disease causing Neutral 
AGS-2 c.1114C>T p.Leu372Phe Tolerated Probably damaging Disease causing Neutral 
AGS-3 c.2336G>A p.Arg779His Tolerated Probably damaging Disease causing Deleterious 
 

































H. sapiens           !
P. troglodytes     !
B. taurus              !
C. familiaris         !
R. norvegicus      !
M. musculus        !
G. gallus               !




















(C)!CARD domain	 Helicase domain	




CARD domain 	 Helicase domain	 Conserved helicase motif	
wt/wt	 wt/wt	
wt/mut	 wt/mut	 wt/mut	








































































   *!
Mapping to human reference genome 
(GRCh37) with Burrows-Wheeler Aligner !
Variant calling with Genome Analysis Toolkit !
Sequencing!
Exome enrichment from genomic DNA!
Variant annotation !
using an in-house program!
Removal of silent single-nucleotide variants!
De novo!
Remove variants;!
•  dbSNP 137 with >0.01 
allele frequency!
•  In-house exome database 
with >0.02 allele 
frequency!






•  dbSNP 137 with >0.01 
allele frequency!
•  In-house exome database 
with >0.05 allele 
frequency!
Figure S1. A flow diagram of the trio-based whole exome sequencing process.  



























































Figure S3. Comparison of the mutant MDA5 reporter activity between the AGS mutants 
and SNPs. Huh7 cells were transfected with a reporter gene containing IFNB1 promoter 
(p-55C1B Luc), along with empty vector, wild-type MDA5, its three AGS mutants, or three 
MDA5 amino acid variations corresponding to other non-synonymous SNPs; namely, 
p.Ala452Val (c.1355C>T), p.Ala788Thr (2362G>A), and p.Arg806Cys (c.2416C>T). 
Luciferase activity was measured 48 hours after transfection. The experiment was performed 
in triplicate and data are mean ± S.E.M. The mean of each triplicate was compared between 
the three AGS mutants and three mutants having other SNPs. Statistical significance was 



























Figure S4. Endogenous expression of the IFIT1 gene in the Huh7 transfection. IFIT1 
expression of the transfected Huh7 cells was measured by RT-qPCR. The relative abundance 
of each transcript was normalized to the expression level of 18S ribosomal RNA. Each 
experiment was performed in triplicate and data are mean ± S.E.M. Statistical significance was 
determined by Student’s t-test. *p<0.01.  
Figure S5. Retrovirally transduced expression of IFIH1 constructs in Ifih1null MEFs. 
 Ifih1null MEFs were transfected with empty retrovirus vector, retrovirus  encoding FLAG-
mouse wild type Ifih1 (WT) or FLAG-mouse Ifih1 with  p.Gly821Ser mutation, or the FLAG-
tagged three AGS mutants of human IFIH1. The FLAG-tagged MDA5 and β-Actin 
accumulation was examined by Western blotting.  
FLAG!
β-ACTIN!
Supplemental table 1 
Exome sequencing summary 
 
AGS-1 AGS-2 AGS-3 
Exome enrichment kit Illumina  Illumina Agilent 
 
TruSeq Exome     
Enrichment Kit 
TruSeq Exome          
Enrichment Kit 
SureSelect Human     
All Exon V5 Kit  
Sequencer  HiSeq 1000 HiSeq 1000 HiSeq 1500 
Mapped region (>=5x) 58384949 57380736 87233940 
Exome target region 62286366 62286366 89659527 
>=x5 coverage (%) 93.7363 92.1240 97.2946 
Total variants 60273 57558 99557 
    
    
Variants after dbSNP137 filtering AGS-1 AGS-2 AGS-3 
  Total 2804 2622 2522 
   Frameshift 111 98 114 
   Nonsense 51 50 47 
   Missense or in-frame indel 2618 2454 2067 
   Splice-site 24 20 294 
    
    
Rare variants AGS-1 AGS-2 AGS-3 
    Total 34 28 102 
     De novo 7 4 28 
     Autosomal recessive 5 2 11 
     Compound heterozygous 12 10 63 
     X-linked 10 12 N.D. 
    
    
Sequence data were mapped against the human reference genome (Genome Reference Consortium Human Build 37) 
using Burrows-Wheeler Aligner software. Variants were called using the Genome Analysis Toolkit, and were 
filtered to remove those with variant quality scores less than 50. Gene annotation of each variant was performed 
using an in-house program. Identified non-synonymous or splice-site variants were filtered to remove those with 
minor allele frequencies (MAF) >0.01 in dbSNP137. For detecting any rare de novo variants, these variants 
observed in family members, identified in Human Genetic Variation Database, or those with MAF >0.02 in our 
in-house exome database were removed. For rare autosomal recessive, compound heterozygous, or X-linked 
variants, those with MAF >0.05 in our in-house database were removed. N.D.; not determined.  
 
Supplemental table 2  Profiles of the AGS individuals 
Clinical findings 
 Age Sex GA BW Disease onset Developmental 
delay 
Other neurological manifestations Chilblain 
lesions 
Extraneural manifestations 
AGS-1 5 yr M 36 wk 2780 g 4 d 
Omphalitis with thrombocytopenia 
Severe Hypertonia, complex febrile seizure, 
microcephaly, spastic quadriplegia 
No Idiopathic interstitial 
pneumonia 
AGS-2 6 yr M 39 wk 3290 g 6 mo 
Developmental delay 
Severe Regression, dystonia, microcephaly, 
quadriplegia 
No Atopic dermatitis 
AGS-3 2 yr F 37 wk 2515 g 5 mo 
Developmental delay 
Severe Complex febrile seizure, dystonia, 
hypotonia, progressive microcephaly, 
spastic quadriplegia 
No Recurrent otitis media, 
sinusitis, periodic fever 
 

































ANA 1:320 None Yes 




















Bilateral spotty in the basal 






Notes: GA, gestational age; BW, birth weight; M, male; F, female; d, day(s); wk, week(s); mo, month(s); yr, year(s); n.d., not done. 
The upper limit of normal CSF neopterin in our institute is 34.6nM at an age of 1-12 months and 25nM at an age of 2-12 years
